Abnormalities of the cytoskeleton and increased cell adhesion to FN1 mediated by BCR::ABL1 have been observed in CML patients, while BCR::ABL1 mutations have been associated with reduced FN1 binding (Li et al., 2007). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.